The board of directors of China Traditional Chinese Medicine Holdings Co. Limited announced that based on the preliminary assessment by the company's management with reference to the unaudited consolidated management accounts of the Group for the six months ended June 30, 2016 (Interim Period), the Group is expected to record an increase of more than 100% in unaudited consolidated net profit attributable to shareholders for the interim period as compared to the unaudited consolidated net profit attributable to shareholders from continuing operations of approximately RMB 243.2 million for the corresponding period in 2015. The significant improvement in the results of the Group was mainly attributable to the full period profit contribution from Jiangyin Tianjiang Pharmaceutical Co. Ltd., a 87.3%-owned subsidiary acquired by the Group in October 2015.